Bioclinical Parameters Driving Decision-Making of Subsequent Lines of Treatment in Metastatic Castration-Resistant Prostate Cancer

Different options are available as second-line treatment of metastatic castrate-resistant prostate cancer: cabazitaxel, abiraterone, and enzalutamide. Phase III studies evaluating cabazitaxel and the two hormonal agents have been shown to significantly prolong overall survival compared to mitoxantro...

Descripción completa

Detalles Bibliográficos
Autores principales: Irelli, A., Bruera, G., Cannita, K., Palluzzi, E., Gravina, G. L., Festuccia, C., Ficorella, C., Ricevuto, E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4058260/
https://www.ncbi.nlm.nih.gov/pubmed/24971356
http://dx.doi.org/10.1155/2014/909623

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4058260/
https://www.ncbi.nlm.nih.gov/pubmed/24971356
http://dx.doi.org/10.1155/2014/909623

Ejemplares similares